Company Description
After nearly 10 years of irreconcilable differences, Daimler and Chrysler have called it quits. The two joined forces in 1998 in a $37 billion deal,...
Key Daimler Financials
| Company Type | Public - NYSE: DAI; German: DAI Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $146,404.8 |
| 2006 Employees | 360,385 |
More Daimler Financials (11 pages)
Latest Daimler Jobs powered by Monster.com
- Compliance Auditor II
- Compliance Auditor II
- Senior Sarbanes-Oxley Analyst
Rankings
- DAX 30
- Dow Jones STOXX 50
- #79 in FT Global 500
Competition
Competitive Landscape for Automobile Manufacture
The major drivers of US demand for autos are employment and interest rates. The profitability of individual companies depends on manufacturing efficiency, product quality, and effective...
Read more about Daimler's competition across multiple industries
Top Daimler Competitors
Sponsored Links
The Business DirectoryDaimler Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman Management Board and Head Mercedes Car Group | Dieter Zetsche | Network | E-mail |
| Member Management Board, Corporate Development | Rüdiger Grube | Network | E-mail |
| Management Board Member, Finance and Controlling, Financial Services, and Corporate Procurement Services | Bodo Uebber | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Current Daimler News
- Karmann urgently seeks fresh orders [Frankfurter Allgemeine Zeitung] (09 May 2008 00:01:00 EDT)
- Kyodo economic news summary -5-+ [Japan Economic Newswire] (08 May 2008 06:10:00 EDT)
- A century of super service [Nottingham Evening Post] (08 May 2008 00:01:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.




